Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 18/20 | 0.84 |
| ▸ | SLC5A1 | P13866 | 10/20 | 0.82 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.82 |
| ▸ | SLC5A11 | Q8WWX8 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18058587 | 1.00 | SLC5A2 (0.84) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL16421583 | 1.00 | SLC5A2 (0.84) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL19620408 | 0.93 | SLC5A2 (0.83) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL14065538 | 0.93 | SLC5A2 (0.83) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL17623722 | 0.91 | SLC5A2 (0.98) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| Dapagliflozin SCHEMBL23542057 | 0.90 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| Dapagliflozin SCHEMBL15281296 | 0.90 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| Dapagliflozin SCHEMBL16001389 | 0.90 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| Dapagliflozin SCHEMBL12781978 | 0.90 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| Dapagliflozin SCHEMBL19867556 | 0.90 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009143020-A1 | METHOD FOR TREATING HYPERURICEMIA EMPLOYING AN SGLT2 INHIBITOR AND COMPOSITION CONTAINING SAME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-11-26 | — | — | WO | disclosed |
| WO-2008002824-A1 | CRYSTALLINE SOLVATES AND COMPLEXES OF (IS) -1, 5-ANHYDRO-L-C- (3- ( (PHENYL) METHYL) PHENYL) -D-GLUCITOL DERIVATIVES WITH AMINO ACIDS AS SGLT2 INHIBITORS FOR THE TREATMENT OF DIABETES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-03 | — | — | WO | disclosed |
| EP-1506211-B1 | C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2007-02-07 | — | — | EP | disclosed |